BN Business News
Add your company to Business Communicator →

Business · 25/02/2019Updated: 10/17/2026 · 1 min read

FDA Reopens Comment Period for Proposed Rule on Institutional Review Board Waiver or Alteration of Informed Consent

Summary

The Food and Drug Administration is reopening the comment period for a proposed rule related to Institutional Review Board waiver or alteration of informed consent for minimal risk clinical investigations, following technical issues with the Federal eRulemaking Portal.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →